Detalhe da pesquisa
1.
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
Alzheimers Dement (N Y)
; 5: 20-26, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30723776